biophBiomedical PhotonicsBiomedical Photonics2413-9432Non-profit partnership for development of domestic photodynamic therapy and photodiagnosis10.24931/2413-9432-2025-14-4-4-10bioph-756Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESИсследование рН-зависимого гидролиза гидразидного производного хлорина е6 как потенциального фотосенсибилизатора для комбинированной противоопухолевой терапииInvestigation of the pH-dependent hydrolysis of a chlorin e6 hydrazide derivative as a potential photosensitizer for combined anticancer therapyМедведевД. Ю.MedvedevD. Y.

Москва 

Moscow 

dy.medvedev@mail.ruГринМ. А.GrinM. A.

Москва

Moscow 

Институт тонких химических технологий, РТУ МИРЭАРоссияInstitute of Fine Chemical Technologies, MIREA – Russian Technological UniversityRussian Federation202512022026144410Copyright © Медведев Д.Ю., Грин М.А., 20262026Медведев Д.Ю., Грин М.А.Medvedev D.Y., Grin M.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pdt-journal.com/jour/article/view/756

Онкологические заболевания представляют собой глобальную проблему здравоохранения, и разработка новых эффективных терапевтических стратегий является актуальной задачей. Химиотерапия и фотодинамическая терапия (ФДТ) являются ключевыми методами лечения, однако их применение сопряжено с побочными эффектами, системной токсичностью и развитием лекарственной устойчивости. В последние годы активно исследуются комбинированные подходы, в том числе с использованием рН-чувствительных систем доставки. Настоящее исследование было посвящено изучению гидролиза гидразидного производного хлорина e6, выступающего в качестве потенциального фотосенсибилизатора (ФС) для комбинированной противоопухолевой терапии. Гидразидные фрагменты, благодаря своей лабильности в слабокислой среде опухолевого микроокружения (pH 4,5-6,0), являются перспективными для создания систем адресной доставки лекарств. Изучение разложения гидразидного фрагмента осуществлялось спектрофотометрически в ацетатном буфере (pH 5,0) в течение 120 мин. Были зафиксированы спектральные изменения (батохромный сдвиг, появление максимума при 688 нм), указывающие на образование протонированного соединения-предшественника. Была продемонстрирована линейная зависимость накопления продукта от времени, характерная для реакций нулевого порядка. Высокий коэффициент детерминации подтвердил адекватность полученной модели. Данный подход обеспечивает контролируемое высвобождение активных компонентов и демонстрирует потенциал разработанного ФС для повышения эффективности ФДТ и снижения системной токсичности химиотерапии.

Oncological diseases represent a global healthcare challenge, and the development of new effective therapeutic strategies remains a pressing task. Chemotherapy and photodynamic therapy (PDT) are key treatment modalities, however, their application is associated with side effects, systemic toxicity, and the development of drug resistance. In recent years, combined approaches, including the use of pH-sensitive delivery systems, have been actively investigated. The present study was dedicated to the investigation of the pH-dependent hydrolysis of a chlorin e6 hydrazide derivative, acting as a potential photosensitizer (PS) for combined anticancer therapy. Hydrazide fragments, due to their lability in the weakly acidic environment of the tumor microenvironment (pH 4.5-6.0), are promising for the creation of targeted drug delivery systems. The decomposition of the hydrazide fragment was studied spectrophotometrically in an acetate buffer (pH 5.0) over 120 minutes. Spectral changes (bathochromic shift, appearance of a maximum at 688 nm) were recorded, indicating the formation of a protonated precursor compound. A linear dependence of product accumulation on time was obtained, characteristic of zero-order reactions. A high coefficient of determination confirmed the adequacy of the obtained model. This approach ensures controlled release of active components and demonstrates the potential of the developed PS for enhancing PDT efficacy and reducing the systemic toxicity of chemotherapy.

хлорин e6фотодинамическая терапиягидразидгидролизchlorin e6photodynamic therapyhydrazidehydrolysisThis work was supported by the Ministry of Science and Higher Education of the Russian Federation under state contract No. FSFZ-2025-0020.Referencesde Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis // The Lancet global health. – 2020. – Vol. 8. – P. e180-e190. doi:10.1016/S2214-109X(19)30488-7.de Martel C., Georges D., Bray F., Ferlay J., Clifford G.M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. The Lancet global health, 2020, vol. 8, pp. e180-e190. doi:10.1016/S2214-109X(19)30488-7.Chen H., Zhang G., Qian Y., Peng Y., Li X., Wang J., Wang J., Hu Y., Xiao H., Zhong Q., Li X., Xie Y., Chen Y., Zhao L., Jing Q., Shan X., Wang Y. Advancements in the Application of the Intersection of Medicine and Engineering in Cancer Research // Cancer Nexus. – 2025. – Vol. 1. – P. e70003. doi:10.1002/cnx2.70003.Chen H., Zhang G., Qian Y., Peng Y., Li X., Wang J., Wang J., Hu Y., Xiao H., Zhong Q., Li X., Xie Y., Chen Y., Zhao L., Jing Q., Shan X., Wang Y. Advancements in the Application of the Intersection of Medicine and Engineering in Cancer Research. Cancer Nexus, 2025, vol. 1, pp. e70003. doi:10.1002/cnx2.70003.Piña-Sánchez P., Chávez-González A., Ruiz-Tachiquín M., Vadillo E., Monroy-García A., Montesinos J.J., Grajales R., Gutiérrez de la Barrera M., Mayani H. Cancer biology, epidemiology, and treatment in the 21st century: Current status and future challenges from a biomedical perspective // Cancer Control. – 2021. – Vol. 28. – P. 10732748211038735. doi:10.1177/10732748211038735.Piña-Sánchez P., Chávez-González A., Ruiz-Tachiquín M., Vadillo E., Monroy-García A., Montesinos J.J., Grajales R., Gutiérrez de la Barrera M., Mayani H. Cancer biology, epidemiology, and treatment in the 21st century: Current status and future challenges from a biomedical perspective. Cancer Control, 2021, vol. 28, pp. 10732748211038735. doi:10.1177/10732748211038735.Tilsed C.M., Fisher S.A., Nowak A.K., Lake R.A., Lesterhuis W.J. Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms of action // Frontiers in oncology. – 2022. – Vol. 12. – P. 960317. doi:10.3389/fonc.2022.960317.Tilsed C.M., Fisher S.A., Nowak A.K., Lake R.A., Lesterhuis W.J. Cancer chemotherapy: Insights into cellular and tumor microenvironmental mechanisms of action. Frontiers in oncology, 2022, vol. 12, pp. 960317. doi:10.3389/fonc.2022.960317.Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: molecular mechanisms of action // European journal of pharmacology. – 2014. – Vol. 740. – P. 364-378. doi:10.1016/j.ejphar.2014.07.025.Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: molecular mechanisms of action. European journal of pharmacology, 2014, vol. 740, pp. 364-378. doi:10.1016/j.ejphar.2014.07.025.Ali I., Wani W.A., Haque A., Saleem K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs // Future medicinal chemistry. – 2013. – Vol. 5. – P. 961-978. doi:10.4155/fmc.13.62.Ali I., Wani W.A., Haque A., Saleem K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future medicinal chemistry, 2013, vol. 5, pp. 961-978. doi:10.4155/fmc.13.62.Mantri Y., Lippard S.J., Baik M.H. Bifunctional binding of cisplatin to DNA: why does cisplatin form 1, 2-intrastrand cross-links with ag but not with GA? // Journal of the American Chemical Society. – 2007. – Vol. 129. – P. 5023-5030. doi:10.1021/ja067631z.Mantri Y., Lippard S.J., Baik M.H. Bifunctional binding of cisplatin to DNA: why does cisplatin form 1, 2-intrastrand cross-links with ag but not with GA?. Journal of the American Chemical Society, 2007, vol. 129, pp. 5023-5030. doi:10.1021/ja067631z.Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis // Cisplatin: Chemistry and biochemistry of a leading anticancer drug. – 1999. – P. 111-134. doi:10.1002/9783906390420.ch4.Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis. Cisplatin: Chemistry and biochemistry of a leading anticancer drug, 1999, pp. 111-134. doi:10.1002/9783906390420.ch4.Chang X., Bian M., Liu L., Yang J., Yang Z., Wang Z., Lu Y., Liu W. Induction of immunogenic cell death by novel platinum-based anticancer agents // Pharmacological Research. – 2023. – Vol. 187. – P. 106556. doi:10.1016/j.phrs.2022.106556.Chang X., Bian M., Liu L., Yang J., Yang Z., Wang Z., Lu Y., Liu W. Induction of immunogenic cell death by novel platinum-based anticancer agents. Pharmacological Research, 2023, vol. 187, pp. 106556. doi:10.1016/j.phrs.2022.106556.Kiyonari S., Iimori M., Matsuoka K., Watanabe S., Morikawa-Ichinose T., Miura D., Niimi S., Saeki H., Tokunaga E., Oki E., Morita M., Kadomatsu K., Maehara Y., Kitao H. The 1, 2-diaminocyclohexane carrier ligand in oxaliplatin induces p53-dependent transcriptional repression of factors involved in thymidylate biosynthesis // Molecular cancer therapeutics. – 2015. – Vol. 14. – P. 2332-2342. :10.1158/1535-7163.MCT-14-0748.Kiyonari S., Iimori M., Matsuoka K., Watanabe S., Morikawa-Ichinose T., Miura D., Niimi S., Saeki H., Tokunaga E., Oki E., Morita M., Kadomatsu K., Maehara Y., Kitao H. The 1, 2-diaminocyclohexane carrier ligand in oxaliplatin induces p53-dependent transcriptional repression of factors involved in thymidylate biosynthesis. Molecular cancer therapeutics, 2015, vol. 14, pp. 2332-2342. doi:10.1158/1535-7163.MCT-14-0748.Johnstone T.C., Suntharalingam K., Lippard S.J. The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs // Chemical reviews. – 2016. – Vol. 116. – P. 3436-3486. doi:10.1021/acs.chemrev.5b00597.Johnstone T.C., Suntharalingam K., Lippard S.J. The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs. Chemical reviews, 2016, vol. 116, pp. 3436-3486. doi:10.1021/acs.chemrev.5b00597.Gandioso A., Shaili E., Massaguer A., Artigas G., González-Cantó A., Woods J.A., Sadler P.J., Marchán V. An integrin-targeted photoactivatable Pt (IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies // Chemical Communications. – 2015. – Vol. 51. – P. 9169-9172. doi:10.1039/c5cc03180j.Gandioso A., Shaili E., Massaguer A., Artigas G., González-Cantó A., Woods J.A., Sadler P.J., Marchán V. An integrin-targeted photoactivatable Pt (IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies. Chemical Communications, 2015, vol. 51, pp. 9169-9172. doi:10.1039/c5cc03180j.Kutlu E., Emen F.M., Kismali G., Kınaytürk N.K., Kılıç D., Karacolak A.I., Demirdogen R.E. Pyridine derivative platinum complexes: Synthesis, molecular structure, DFT and initial anticancer activity studies // Journal of Molecular Structure. – 2021. – Vol. 1234. – P. 130191. doi:10.1016/j.molstruc.2021.130191.Kutlu E., Emen F.M., Kismali G., Kınaytürk N.K., Kılıç D., Karacolak A.I., Demirdogen R.E. Pyridine derivative platinum complexes: Synthesis, molecular structure, DFT and initial anticancer activity studies. Journal of Molecular Structure, 2021, vol. 1234. pp. 130191. doi:10.1016/j.molstruc.2021.130191.Zorzi D., Laurent A., Pawlik T.M., Lauwers G.Y., Vauthey J.N., Abdalla E.K. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases // Journal of British Surgery. – 2007. – Vol. 94. – P. 274-286. doi:10.1002/bjs.5719.Zorzi D., Laurent A., Pawlik T.M., Lauwers G.Y., Vauthey J.N., Abdalla E.K. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Journal of British Surgery, 2007, vol. 94, pp. 274-286. doi:10.1002/bjs.5719.Anderegg G., Wanner H. Pyridine derivatives as complexing agents. XIII. The stability of the palladium (II) complexes with pyridine, 2, 2′-bipyridyl, and 1, 10-phenanthroline // Inorganica chimica acta. – 1986. – Vol. 113. – P. 101-108. doi:10.1016/S0020-1693(00)82229-X.Anderegg G., Wanner H. Pyridine derivatives as complexing agents. XIII. The stability of the palladium (II) complexes with pyridine, 2, 2′-bipyridyl, and 1, 10-phenanthroline. Inorganica chimica acta, 1986, vol. 113, pp. 101-108. doi:10.1016/S0020-1693(00)82229-X.Dąbrowski J.M., Arnaut L.G. Photodynamic therapy (PDT) of cancer: from local to systemic treatment // Photochemical & Photobiological Sciences. – 2015. – Vol. 14. – P. 1765-1780. doi:10.1039/c5pp00132c.Dąbrowski J.M., Arnaut L.G. Photodynamic therapy (PDT) of cancer: from local to systemic treatment. Photochemical & Photobiological Sciences, 2015, vol. 14, pp. 1765-1780. doi:10.1039/c5pp00132c.Li X., Lovell J.F., Yoon J., Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer // Nature reviews Clinical oncology. – 2020. – Vol. 17. – P. 657-674. doi:10.1038/s41571-020-0410-2.Li X., Lovell J.F., Yoon J., Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nature reviews Clinical oncology, 2020, vol. 17, pp. 657-674. doi:10.1038/s41571-020-0410-2.Donohoe C., Senge M.O., Arnaut L.G., Gomes-da-Silva L.C. Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity // Biochimica et Biophysica Acta (BBA)- Reviews on Cancer. – 2019. – Vol. 1872. – P. 188308. doi:10.1016/j.bbcan.2019.07.003.Donohoe C., Senge M.O., Arnaut L.G., Gomes-da-Silva L.C. Cell death in photodynamic therapy: From oxidative stress to anti-tumor immunity. Biochimica et Biophysica Acta (BBA)- Reviews on Cancer, 2019, vol. 1872, pp. 188308. doi:10.1016/j.bbcan.2019.07.003.Li X., Lee S., Yoon J. Supramolecular photosensitizers rejuvenate photodynamic therapy // Chemical Society Reviews. – 2018. – Vol. 47. – P. 1174-1188. doi:10.1039/c7cs00594f.Li X., Lee S., Yoon J. Supramolecular photosensitizers rejuvenate photodynamic therapy. Chemical Society Reviews, 2018, vol. 47, pp. 1174-1188. doi:10.1039/c7cs00594f.Kaczorowska A., Malinga-Drozd M., Kałas W., Kopaczyńska M., Wołowiec S., Borowska K. Biotin-containing third generation glucoheptoamidated polyamidoamine dendrimer for 5-aminolevulinic acid delivery system // International Journal of Molecular Sciences. – 2021. – Vol. 22. – P. 1982. doi:10.3390/ijms22041982.Kaczorowska A., Malinga-Drozd M., Kałas W., Kopaczyńska M., Wołowiec S., Borowska K. Biotin-containing third generation glucoheptoamidated polyamidoamine dendrimer for 5-aminolevulinic acid delivery system. International Journal of Molecular Sciences, 2021, vol. 22, pp. 1982. doi:10.3390/ijms22041982.Dąbrowski J.M., Arnaut L.G. Photodynamic therapy (PDT) of cancer: from local to systemic treatment // Photochemical & Photobiological Sciences. – 2015. – Vol. 14. – P. 1765-1780. doi:10.1039/c5pp00132c.Dąbrowski J.M., Arnaut L.G. Photodynamic therapy (PDT) of cancer: from local to systemic treatment. Photochemical & Photobiological Sciences, 2015, vol. 14, pp. 1765-1780. doi:10.1039/c5pp00132c.Wentrup R., Winkelmann N., Mitroshkin A., Prager M., Voderholzer W., Schachschal G., Jürgensen C., Büning C. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma // Gut and liver. – 2016. – Vol. 10. – P. 470. doi:10.5009/gnl15175.Wentrup R., Winkelmann N., Mitroshkin A., Prager M., Voderholzer W., Schachschal G., Jürgensen C., Büning C. Photodynamic therapy plus chemotherapy compared with photodynamic therapy alone in hilar nonresectable cholangiocarcinoma. Gut and liver, 2016, vol. 10, pp. 470. doi:10.5009/gnl15175.Li B., Meng Z., Li Q., Huang X., Kang Z., Dong H., Chen J., Sun J., Dong Y., Li J., Jia X., Sessler J.L., Meng Q., Li C. A pH responsive complexation-based drug delivery system for oxaliplatin // Chemical science. – 2017. – Vol. 8. – P. 4458-4464. doi:10.1039/c7sc01438d.Li B., Meng Z., Li Q., Huang X., Kang Z., Dong H., Chen J., Sun J., Dong Y., Li J., Jia X., Sessler J.L., Meng Q., Li C. A pH responsive complexation-based drug delivery system for oxaliplatin. Chemical science, 2017, vol. 8, pp. 4458-4464. doi:10.1039/c7sc01438d.Liu J., Huang Y., Kumar A., Tan A., Jin S., Mozhi A., Liang X.J. pHsensitive nano-systems for drug delivery in cancer therapy // Biotechnology advances. – 2014. – Vol. 32. – P. 693-710. doi:10.1016/j.biotechadv.2013.11.009.Liu J., Huang Y., Kumar A., Tan A., Jin S., Mozhi A., Liang X.J. pHsensitive nano-systems for drug delivery in cancer therapy. Biotechnology advances, 2014, vol. 32, pp. 693-710. doi:10.1016/j.biotechadv.2013.11.009.Liu R., Zhang Y., Zhao X., Agarwal A., Mueller L.J., Feng P. pHresponsive nanogated ensemble based on gold-capped mesoporous silica through an acid-labile acetal linker // Journal of the American Chemical Society. – 2010. – Vol. 132. – P. 1500-1501. doi:10.1021/ja907838s.Liu R., Zhang Y., Zhao X., Agarwal A., Mueller L.J., Feng P. pHresponsive nanogated ensemble based on gold-capped mesoporous silica through an acid-labile acetal linker. Journal of the American Chemical Society, 2010, vol. 132, pp. 1500-1501. doi:10.1021/ja907838s.Cappellesso F., Mazzone M., Virga F. Acid affairs in anti-tumour immunity // Cancer cell international. – 2024. – Vol. 24. – P. 354. doi:10.1186/s12935-024-03520-0.Cappellesso F., Mazzone M., Virga F. Acid affairs in anti-tumour immunity. Cancer cell international, 2024, vol. 24, pp. 354. doi:10.1186/s12935-024-03520-0.Liberti M.V., Locasale J.W. The Warburg effect: how does it benefit cancer cells? // Trends in biochemical sciences. – 2016. – Vol. 41. – P. 211-218. doi:10.1016/j.tibs.2015.12.001.Liberti M.V., Locasale J.W. The Warburg effect: how does it benefit cancer cells?. Trends in biochemical sciences, 2016, vol. 41, pp. 211-218. doi:10.1016/j.tibs.2015.12.001.Kirin N.S., Ostroverkhov P.V., Usachev M.N., Birin K.P., Grin M.A. Platinum (II) complexes based on derivatives of natural chlorins with pyridine-containing chelate groups as prototypes of drugs for combination therapy in oncology // Fine Chemical Technologies. – 2024. – Vol. 19. – P. 310-326. doi:10.32362/2410-6593-2024-19-4-310-326.Kirin N.S., Ostroverkhov P.V., Usachev M.N., Birin K.P., Grin M.A. Platinum (II) complexes based on derivatives of natural chlorins with pyridine-containing chelate groups as prototypes of drugs for combination therapy in oncology. Fine Chemical Technologies, 2024, vol. 19, pp. 310-326. doi:10.32362/2410-6593-2024-19-4-310-326.Pandit R.P., Thapa Magar T.B., Shrestha R., Lim J., Gurung P., Kim Y.W. Isolation, identification, and biological activities of a new chlorin e6 derivative // International Journal of Molecular Sciences. – 2024. – Vol. 25. – P. 7114. doi:10.3390/ijms25137114.Pandit R.P., Thapa Magar T.B., Shrestha R., Lim J., Gurung P., Kim Y.W. Isolation, identification, and biological activities of a new chlorin e6 derivative. International Journal of Molecular Sciences, 2024, vol. 25, pp. 7114. doi:10.3390/ijms25137114.Fu R.G., Sun Y., Sheng W.B., Liao D.F. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm // European journal of medicinal chemistry. – 2017. – Vol. 136. – P. 195-211. doi:10.1016/j.ejmech.2017.05.016.Fu R.G., Sun Y., Sheng W.B., Liao D.F. Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. European journal of medicinal chemistry, 2017, vol. 136, pp. 195- 211. doi:10.1016/j.ejmech.2017.05.016.

The authors declare that there are no conflicts of interest present.